Translating GRI 0621 from Preclinical Models to Phase 2a IPF Signals
Time: 9:00 am
day: Conference Day Two
Details:
- Highlight the impact of GRI 0621 in resolving inflammation and fibrosis in preclinical bleomycin-induced models and how this informed clinical design
- Review preliminary Phase 2a results in IPF patients and discuss implications for dose, patient selection, and endpoint refinement
- Explore how early clinical insights are feeding back into preclinical strategy to sharpen target validation and accelerate development
- Consider how Phase 2a signals are being evaluated to de-risk and prepare for a potential Phase 2b/3 transition strategy
